In the PEARL trial (1 year, low doses), rapamycin is well tolerated with modest effects on some markers. ConfidenceDebated Level of evidence●●●●●○ Randomized clinical trial Observed inHuman MissionMap of aging (12 hallmarks) ConceptsDisabled macroautophagyRapamycin (and analogues: everolimus)